Hormonal
Tirzepatide, a dual GLP-1/GIP receptor agonist administered once weekly, significantly reduces body weight and improves glycemic control in patients with type 2 diabetes and obesity compared to placebo and other active comparators.
Tirzepatide is a once-weekly injection that helps your body manage blood sugar and lose weight more effectively than many existing treatments. It works by mimicking hormones that regulate appetite and insulin. You start with a low dose to minimize stomach upset and gradually increase it. It is approved for both type 2 diabetes and obesity management.
Tirzepatid je duální agonista receptorů pro glucagon-like peptid 1 (GLP-1) a glukózo-dependentní inzulinotropní polypeptid (GIP)... Po 40 týdnech užívání tirzepatid vykázal superioritu vůči placebu v ovlivnění HbA1c, glykemie nalačno, tělesné hmotnosti... Průměrný HbA1c klesl za 40 týdnů studie o 20–23 mmol/mol a vzrostl o 0,4 mmol/mol u placeba... v průběhu léčby došlo k redukci hmotnosti od 7 do 9,5 kg v závislosti na dávce.
Why this rating
Based on multiple Phase 3 randomized controlled trials (SURPASS 1-6, SURMOUNT 1-4) with large sample sizes and FDA/EMA approval.
Source
Tirzepatide - a promising medication for cardiovascular protection and treatment of Type 2 diabetes and obesity
Pavlína Piťhová · Vnitřní lékařství · 2025
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →